---
title: "NexGel shareholders constrain structural changes at annual meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295023136.md"
description: "At its July 31, 2026 annual meeting, NexGel shareholders elected six new directors and approved executive compensation and auditor ratification. However, they rejected key structural proposals, including reincorporation in Nevada, increasing authorized shares to 100 million, and a reverse stock split. These rejections constrain management's ability to alter the corporate domicile or share base, signaling investor caution regarding significant structural changes despite supporting financing arrangements."
datetime: "2026-08-05T21:53:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295023136.md)
  - [en](https://longbridge.com/en/news/295023136.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295023136.md)
generator: "portal-rs"
---

# NexGel shareholders constrain structural changes at annual meeting

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

NexGel Inc ( (NXGL) ) has shared an update.

At NexGel Inc.’s 2026 annual meeting of stockholders held on July 31, 2026, shareholders elected six directors—Adam Levy, Steven Glassman, Steven A. Ciardiello, Dr. Jerome B. Zeldis, Brian J. Kieser and Kevin M. Harris—to serve until the 2027 meeting, while noting that Scott R. Henry had resigned from the board earlier, effective July 1, 2026. Investors also approved, in line with Nasdaq Listing Rule 5635(d), the issuance of shares tied to convertible notes and warrants from April and May 2026 private placements, endorsed executive compensation on an advisory basis, and ratified Turner, Stone & Company, L.L.P. as auditor for the 2026 fiscal year.

However, shareholders rejected three key capital-structure proposals: a move to reincorporate NexGel from Delaware to Nevada, an increase in authorized common shares from 25 million to 100 million, and a discretionary reverse stock split in a range of 1-for-2 to 1-for-10. These votes constrain management’s flexibility to alter the company’s share base and corporate domicile in the near term, signaling investor caution around significant structural changes while still supporting the company’s financing arrangements and governance framework.

The most recent analyst rating on (NXGL) stock is a Buy  
 with a $2.00 price target.  
 To see the full list of analyst forecasts on NexGel Inc stock,  
 see the NXGL Stock Forecast page. 

**Spark’s Take on NXGL Stock**

According to Spark, TipRanks’ AI Analyst, NXGL is a Neutral.

The score is primarily held back by weak financial performance (ongoing losses, negative operating/free cash flow, and higher leverage) and bearish technical positioning (trading below all key moving averages). Partially offsetting this is a more constructive earnings-call outlook tied to the BioNX acquisition’s projected revenue step-up and expected profitability accretion, with supportive—though financing-dependent—recent corporate actions.

To see Spark’s full report on NXGL stock,  
 click here. 

**More about NexGel Inc**

NexGel Inc. is a publicly traded company that manufactures and markets hydrogel-based products, with its common stock listed on Nasdaq. The company focuses on leveraging specialty hydrogel technology across consumer and medical applications, and its capital-raising activities, including recent private placements, are central to funding ongoing operations and growth initiatives.

**Average Trading Volume:** 243,319

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $4.9M

For an in-depth examination of NXGL stock, go to TipRanks’ Overview page.

### Related Stocks

- [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)
- [NXGLW.US](https://longbridge.com/en/quote/NXGLW.US.md)

## Related News & Research

- [NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue](https://longbridge.com/en/news/296106108.md)
- [Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition](https://longbridge.com/en/news/296183101.md)
- [Blue Moon Metals wins Nevada permits to start construction at Springer tungsten project](https://longbridge.com/en/news/296539526.md)
- [Vivos Therapeutics opens Henderson, Nevada sleep testing and treatment center, targets over $10 million annual capacity](https://longbridge.com/en/news/296505979.md)
- [Toogood Gold Reports Findings from Dr. Stuart Simmons' Technical Review of Table Mountain Project, Nevada | TGGCF Stock News](https://longbridge.com/en/news/296219362.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**